UBS Group’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

UBS Group’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,736	Closed	-$27K	–	8924
2015 Q4	$27K	Buy	+1,736	New	+$19.2K	﹤0.01%	6453
2015 Q3	–	Sell	-1,759	Closed	-$7K	–	9140
2015 Q2	$7K	Sell	1,759 -3,766	-68%	-$16K	﹤0.01%	7761
2015 Q1	$22K	Buy	+5,525	New	+$24.8K	﹤0.01%	6927

Other funds holding KBIO

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

UBS Group's KBIO Position: Q1 2016 in Review

UBS Group sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q1 2016, closing a stake of 1,736 shares — an estimated $27K sold.

UBS Group first reported a position in KBIO in Q1 2015 and held it in 3 quarters. The position peaked at $27K in Q4 2015. 1 fund tracked by Wall St. Rank holds KBIO as of Q1 2016.

UBS Group reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q1 2016 after selling out during the quarter.
UBS Group sold 1,736 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q1 2016, an estimated $27K.
UBS Group first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q1 2015 and held it in 3 quarters.
UBS Group's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $27K in Q4 2015.
1 fund tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q1 2016.

Based on UBS Group's 13F filing for Q1 2016, filed 12 May 2016.